دورية
Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants
| العنوان: | Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants |
|---|---|
| المؤلفون: | Pfiffner, Miriam, Gotta, Verena, Pfister, Marc, Vonbach, Priska, Berger-Olah, Eva |
| المصدر: | Archives of Disease in Childhood; 2023, Vol. 108 Issue: 1 p56-61, 6p |
| مستخلص: | ObjectivesIntranasal nalbuphine could be a safe, efficacious and non-invasive alternative to parenteral pain medication in infants. We aimed to assess pharmacokinetics (PK) and tolerability of intranasal and intravenous nalbuphine administration in infants.MethodsProspective open-label study including infants 1–3 months of age admitted to the emergency department, receiving nalbuphine for procedural pain management. Patients were alternately allocated to a single nalbuphine dose of 0.05 mg/kg intravenously or 0.1 mg/kg intranasally. Nalbuphine PK samples were collected 15, 30 and 120–180 min after dosing. Area under the concentration time curve (AUC0-Tlast) was calculated by non-compartmental analysis (NCA) and compared by Wilcoxon test. Neonatal Infant Pain Score was assessed during nalbuphine administration and the following interventions: venous access, urinary catheterisation, lumbar puncture.ResultsOut of 52 study subjects receiving nalbuphine, 31 were eligible for NCA (11 intravenous, 20 intranasal). Median AUC0-Tlastafter 0.05 mg/kg intravenously was 8.7 (IQR: 8.0–18.6) µg×L/hour vs 7.6 (5.4–10.4) µg×L/hour after intranasal administration of 0.1 mg/kg (p=0.091). Maximum serum concentration (Cmax) was observed 30 min after intranasal administration (3.5–5.6 µg/L). During intravenous and intranasal nalbuphine administration, mild to no pain was recorded in 71% and 67% of study subjects, respectively.ConclusionThis is the first study investigating intranasal administration of nalbuphine in infants suggesting an intranasal bioavailability close to 50%. Non-invasive intranasal application was well tolerated. Additional studies are warranted to optimise dosing and timing of interventions as Cmaxis delayed by half an hour after intranasal administration.Trial registration numberNCT03059511. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00039888 14682044 |
|---|---|
| DOI: | 10.1136/archdischild-2022-323807 |